Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED Phase 3

Wilate in Subjects With Von Willebrand Disease Who Undergo Surgery

NCT01365546 · View on ClinicalTrials.gov ↗

Study Summary

Proportion of surgeries in which the primary endpoint (overall assessment) is classified as success.

Interventions

  • BIOLOGICAL human VWF/FVIII concentrate

Study Locations (15)

Other

  • SHAT Joan Pavel — Sofia
  • Azienda Ospedaliero Universitaria Careggi — Florence
  • Granda Ospedale Maggiore Policlinico — Milan
  • ULSS6 Vicenza Ematologia — Vicenza
  • Sultan Quaboos University Hospital — Muscat
  • Instytut Hematologii i Transfuzjologii — Warsaw
  • Fundeni Clinical Institute — Bucharest
  • Louis Turcanu Childrens Emergency Hospital — Timișoara
  • Hemophilia Comprehensive Care Center — Johannesburg
  • Ege University — Izmir

Indiana

  • Indiana Hemophilia and Thrombosis Center — Indianapolis

North Carolina

  • UNC-CH Comprehensive Hemophilia Center — Chapel Hill

Wisconsin

  • Blood Center of Wisconsin — Milwaukee

Pune

  • Sahyadri Specialty Hospital — Pune

Tamil Nadu

  • Christian Medical College — Vellore

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2011-06
Est. Completion 2014-04
Phase Phase 3

Sponsor

Octapharma

73 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01365546

The ClinicalTrials.gov registry entry for NCT01365546 describes a study currently listed as completed. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Octapharma, which has 73 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Prevent Bleeding in Major Surgery appearing as the primary indexed condition, and to 1 intervention — of which human VWF/FVIII concentrate is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT01365546 reports 15 study locations spanning 6 distinct geographic areas — top geographies include Other, Indiana, North Carolina. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT01365546 about?

NCT01365546 is a clinical study titled "Wilate in Subjects With Von Willebrand Disease Who Undergo Surgery". Proportion of surgeries in which the primary endpoint (overall assessment) is classified as success.

What is the current status of trial NCT01365546?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 30 participants. The study started on 2011-06. Estimated completion is 2014-04.

What conditions does trial NCT01365546 study?

This clinical trial studies the following conditions: Prevent Bleeding in Major Surgery. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT01365546?

The interventions under investigation include: human VWF/FVIII concentrate (BIOLOGICAL). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT01365546?

This trial is sponsored by Octapharma, which has 73 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT01365546 being conducted?

This trial has 15 study locations across Indiana, North Carolina, Wisconsin, Pune, Tamil Nadu. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial